Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide in High-Risk Nonmetastatic Prostate Cancer
NCT02319837Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Dec 2014
- Primary completion
- Jan 2023
- Modality
- Small Molecules
- Countries
- 17
01
Overview
Phase 3, randomised, double-blind trial of enzalutamide in prostate cancer (PCa) (3 arms), sponsored by Pfizer. Primary endpoint: Metastasis-free Survival at Month 98. Started Dec 2014; status: active, not recruiting.
02
Drugs
enzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02319837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02319837.